Di Perri G - Search Results

1

Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators. Soriano V, et al. Among authors: di perri g. Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745. Antivir Ther. 2011. PMID: 21555816 Clinical Trial.

2

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G. Antinori A, et al. Among authors: di perri g. Antivir Ther. 2006;11(2):233-43. Antivir Ther. 2006. PMID: 16640104

3

A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.

D'Avolio A, Sciandra M, Siccardi M, Baietto L, Gonzalez de Requena D, Bonora S, Di Perri G. D'Avolio A, et al. Among authors: di perri g. J Chromatogr Sci. 2008 Jul;46(6):524-8. doi: 10.1093/chromsci/46.6.524. J Chromatogr Sci. 2008. PMID: 18647474

4

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies.

Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Monforte Ad, et al. AIDS. 2008 Oct 18;22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77. AIDS. 2008. PMID: 18832878 Free PMC article.

5

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.

6

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Rodríguez-Nóvoa S, Labarga P, D'avolio A, Barreiro P, Albalate M, Vispo E, Solera C, Siccardi M, Bonora S, Di Perri G, Soriano V. Rodríguez-Nóvoa S, et al. Among authors: di perri g. AIDS. 2010 Apr 24;24(7):1064-6. doi: 10.1097/QAD.0b013e32833202e2. AIDS. 2010. PMID: 20299966

7

Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.

De Luca A, Di Giambenedetto S, Maserati R, Gianotti N, Narciso P, Antinori A, Di Perri G, Prosperi MC, Baldanti F, Micheli V, Zazzi M, Perno CF, Santoro MM; TMC114-C226 study group; ARCA study group. De Luca A, et al. Among authors: di perri g, di giambenedetto s. Antivir Ther. 2011;16(4):489-97. doi: 10.3851/IMP1799. Antivir Ther. 2011. PMID: 21685536

8

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.

Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Bonora S, et al. Among authors: di perri g. Antivir Ther. 2011;16(4):499-504. doi: 10.3851/IMP1802. Antivir Ther. 2011. PMID: 21685537

9

Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.

Nicastri E, Tommasi C, Abbate I, Bonora S, Tempestilli M, Bellagamba R, Viscione M, Rozera G, Gallo AL, Ivanovic J, Amendola A, Pucillo L, Di Perri G, Capobianchi MR, Narciso P. Nicastri E, et al. Among authors: di perri g. Antivir Ther. 2011;16(6):797-803. doi: 10.3851/IMP1833. Antivir Ther. 2011. PMID: 21900711

10

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Petoumenos K, et al. J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426. J Int AIDS Soc. 2012. PMID: 23078769 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

728 results

Search Page

Filters